The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC).
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Pfizer
 
Giulia Costanza Leonardi
No Relationships to Disclose
 
Sasha Kravets
No Relationships to Disclose
 
Suzanne Eleanor Dahlberg
Patents, Royalties, Other Intellectual Property - Patent pending for a statistical model assessing tumor growth (Inst)
 
Alexander E. Drilon
Honoraria - AstraZeneca; Blueprint Medicines; Exelixis; Genentech/Roche; Ignyta; Loxo
Consulting or Advisory Role - ARIAD
Research Funding - Foundation Medicine
 
Sinead Noonan
Employment - Merck
 
D. Ross Camidge
No Relationships to Disclose
 
Sai-Hong Ignatius Ou
Honoraria - Pfizer; Roche Pharma AG
Consulting or Advisory Role - Pfizer; Roche/Genentech
Speakers' Bureau - Boehringer Ingelheim; Genentech
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Daniel Botelho Costa
Consulting or Advisory Role - ARIAD; Pfizer
 
Shirish M. Gadgeel
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Genentech/Roche
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
 
Conor Ernst Steuer
Consulting or Advisory Role - EMD Serono
 
Patrick M. Forde
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Celgene
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Kyowa Hakko Kirin (Inst); Novartis (Inst)
 
Viola Weijia Zhu
No Relationships to Disclose
 
Yoko Korenaga Fukuda
No Relationships to Disclose
 
Jeffrey W. Clark
Research Funding - Pfizer (Inst)
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Merrimack; Pfizer; Roche
Research Funding - Astellas Pharma; AstraZeneca
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - Sanomics Limited
Stock and Other Ownership Interests - Sanomics Limited
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Taiho Pharmaceutical (Inst)
 
Lynette M. Sholl
Consulting or Advisory Role - Genentech
Travel, Accommodations, Expenses - Mirati Therapeutics
Other Relationship - Research to Practice
 
Rebecca Suk Heist
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim
Research Funding - Abbvie (Inst); Celgene (Inst); Debiopharm Group (Inst); Incyte (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Roche (Inst); Takeda (Inst)